|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
      |
|||||||||||||
 |
 |
|||||||||||||
   
 |
||||||||||||||
Thomas D'Alonzo
CEO
Mr. D'Alonzo has over 20 years of pharmaceutical executive experience. From 1996 to 1999, Mr. D'Alonzo served as President and Chief Operating Officer of Pharmaceutical Product Development, Inc. ("PPD"), a publicly traded drug discovery and development services company. Before joining PPD, he served as President and Chief Executive Officer of GENVEC, Inc. (gene therapy biotech) from 1993 to 1996. From 1983 to 1993, Mr. D'Alonzo held positions of increasing responsibility within Glaxo Inc., including President of Glaxo, Inc. Mr. D'Alonzo is currently a director of the following publicly traded companies: Salix Pharmaceuticals, Inc., BioDelivery Sciences Inc., and Amarillo BioSciences, Inc. Additionally, he serves on the board of two private companies, DARA BioScience, Inc. and Plexigen, Inc.
Mr. D'Alonzo received a B.S. degree in Business Administration from the University of Delaware and a law degree from the University of Denver College of Law.
These statements have not been reviewed by the FDA.
This website is not meant as a substitute for professional medical advice.
|
|
 |
|
